Clinical Trial Update: Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 [Phase 3]

View source ↗

Summary

Phase 3 trial update on hydroxychloroquine and favipiravir for mild to moderate COVID-19 evaluating efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov-2

Drugs mentioned

• Favipiravir (favipiravir)
• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: Ministry of Health, Turkey | Conditions: Sars-CoV2, COVID-19 | Phase 3 | Status: UNKNOWN